Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer-Verlag
Subjects
More information
Scope and Contents
Contents
Introduction
Cerebral atrophy is a compound measure of the neurodegenerative component of multiple sclerosis (MS) and a conceivable outcome measure for clinical trials monitoring the effect of neuroprotective agents. In this study, we evaluate the rate of cerebral atrophy in a 6-month period, investigate the predictive and explanatory value of o...
Alternative Titles
Full title
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2938443
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2938443
Other Identifiers
ISSN
0028-3940
E-ISSN
1432-1920
DOI
10.1007/s00234-009-0645-1
